search
Back to results

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Primary Purpose

Melanoma

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
encorafenib
binimetinib
pembrolizumab
ipilimumab
nivolumab
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Melanoma focused on measuring BRAF, BRAF V600E/K melanoma, metastatic melanoma, advanced melanoma, skin cancer, portside

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female participants ≥18 years of age at the time of informed consent. Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition. Documented evidence of a BRAF V600E or V600K mutation. Submission of adequate tumor tissue for central laboratory testing of BRAF V600E-mutation and biomarkers is required for all participants during the screening period and prior to randomization. Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) Must have anti-PD-1 resistant disease (primary or secondary) with confirmed disease progression per RECIST v1.1 either during or after receipt of an approved anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according to the SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020). Have at least one measurable lesion per RECIST v1.1. ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50% by cardiac imaging. Exclusion Criteria: Mucosal or ocular melanoma. Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment with chronic systemic steroid therapy or any other form of immunosuppressive therapy within the past 2 years. Clinically significant cardiovascular diseases. History of thromboembolic or cerebrovascular events ≤12 weeks prior to randomization. History or current evidence of RVO or current risk factors for RVO. Concurrent neuromuscular disorder that is associated with the potential of elevated CK. Active bacterial, fungal, or viral infection requiring systemic therapeutic treatment within 2 weeks prior to randomization. Current non-infectious pneumonitis/interstitial lung disease or history of noninfectious pneumonitis/interstitial lung disease requiring steroids. Prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases. Participants who permanently discontinued prior anti-PD-1 therapy due to toxicity or will be unable to tolerate combination therapy based on investigator judgement are excluded. Prior treatment with ipilimumab; prior combined immunotherapy blockade with anti-PD-1/L-1; prior treatment with a BRAFi and/or MEKi; or previous administration of an investigational anti-cancer agent for the adjuvant or first-line treatment of melanoma prior to randomization.

Sites / Locations

  • Universitaetsklinikum Heidelberg
  • Universitaetsklinikum Tuebingen
  • Medizinische Hochschule HannoverRecruiting
  • Universitaetsklinikum Essen
  • Fachklinik Hornheide
  • Universitätsklinikum Leipzig
  • Helios Klinikum Erfurt
  • A.O.U. Policlinico Paolo GiacconeRecruiting
  • Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
  • Azienda Ospedaliero Universitaria SeneseRecruiting
  • AO Santa Maria della Misericordia
  • Ospedale San Martino
  • Istituto Europeo di Oncologia IRCCS
  • Istituto Nazionale Tumori IRCCS Fondazione PascaleRecruiting
  • Pratia MCM Krakow
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko - Mazurskim Centrum Onkologii
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
  • Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica
  • Narodny onkologicky ustavRecruiting
  • Nemocnica na okraji mesta, n.o.
  • POKO Poprad, s.r.o., Ambulancia klinickej onkologie
  • Hospital Germans Trias i Pujol
  • Hospital Universitari Vall d'HebronRecruiting
  • Institut Català d'Oncologia - L'Hospitalet
  • Hospital General Universitario de Valencia
  • Hospital General Universitario de AlicanteRecruiting
  • Hospital Clínic de Barcelona
  • Hospital General Universitario Gregorio MarañonRecruiting
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario Virgen Macarena
  • Hospital Universitario Miguel Servet

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Triplet

Doublet

Arm Description

encorafenib and binimetinib in combination with pembrolizumab

ipilimumab and nivolumab

Outcomes

Primary Outcome Measures

Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1

Secondary Outcome Measures

Progression Free Survival in each treatment arm
Overall Survival in each treatment arm
Duration of Response (CR or PR) in each treatment arm
Disease Control Rate (proportion of participants with a confirmed best overall response of CR, PR or SD) in each treatment arm
Time to Response (CR or PR)
Progression Free Survival 2 in each treatment arm
Incidence and severity of Adverse Events (AEs) and changes in clinical laboratory parameters, vital signs, and cardiac assessments.
Number of participants with treatment emergent Adverse Events as as assessed per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 4.03).
Patient Reported Outcomes using EORTC QLQ-C30 questionnaires in each treatment arm
EORTC (European Organization for Research and Treatment of Cancer) QLQ-30 includes 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/Quality of Life scale
Patient Reported Outcomes using EuroQOL EQ-5D-5L questionnaires in each treatment arm
The EQ-5D-5L is a standardized measure of health utility that provides a single index value of health status and contains 1 item for each of 5 dimensions of HRQoL (ie, mobility, self-care, usual activities, pain or discomfort, and anxiety or depression).
BRAF V600E/K Variant Allele Frequency and/or overall mean Variant Allele Frequency from circulating tumour DNA analysis in each treatment arm

Full Information

First Posted
April 3, 2023
Last Updated
October 6, 2023
Sponsor
Pfizer
Collaborators
Merck Sharpe & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05926960
Brief Title
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Acronym
PORTSIDE
Official Title
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 13, 2023 (Actual)
Primary Completion Date
May 23, 2025 (Anticipated)
Study Completion Date
May 23, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer
Collaborators
Merck Sharpe & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to learn about the effects of 3 study medicines (encorafenib, binimetinib, pembrolizumab) compared to 2 study medicines (ipilimumab and nivolumab) given for the treatment of melanoma. Melanoma is a type of cancer that starts in the cells that give color to your skin. The study is seeking participants who: have advanced or metastatic melanoma (has spread to other parts of the body); have a certain abnormal gene called "BRAF". have taken nivolumab or pembrolizumab treatment before this study. Participants will either receive: pembrolizumab given by intravenous infusion (directly into a vein) every 3 weeks at the study clinic. Participants will also receive encorafenib and binimetinib by mouth every day at home, or will receive ipilimumab and nivolumab given by intravenous infusion (directly into a vein) every 3 weeks at the study clinic 4 times. This will be followed by nivolumab given by intravenous infusion every 4 weeks at the study clinic. Both pembrolizumab and nivolumab will be given for a maximum of around 2 years. However, there is no time limit for encorafenib and binimetinib treatment. The study team will see how each participant is doing after receiving the study treatments during regular visits to the study clinic.
Detailed Description
The purpose of the study is to compare the efficacy of a triplet therapy (encorafenib, binimetinib, pembrolizumab) versus a doublet/control therapy (nivolumab and ipilimumab). Participants will have metastatic or unresectable locally advanced BRAF V600E/K-mutant melanoma, which progressed during or after prior treatment in the adjuvant or first-line metastatic setting, with an approved anti-PD-1 monotherapy (pembrolizumab or nivolumab), Approximately 150 participants will be randomized in a 1:1 ratio to the triplet or the doublet/control therapy (75 participants in each arm). Randomization will be stratified by baseline serum LDH level, and by type of PD-1 resistance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma
Keywords
BRAF, BRAF V600E/K melanoma, metastatic melanoma, advanced melanoma, skin cancer, portside

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Triplet
Arm Type
Experimental
Arm Description
encorafenib and binimetinib in combination with pembrolizumab
Arm Title
Doublet
Arm Type
Active Comparator
Arm Description
ipilimumab and nivolumab
Intervention Type
Drug
Intervention Name(s)
encorafenib
Other Intervention Name(s)
BRAFTOVI
Intervention Description
encorafenib
Intervention Type
Drug
Intervention Name(s)
binimetinib
Other Intervention Name(s)
MEKTOVI
Intervention Description
binimetinib
Intervention Type
Drug
Intervention Name(s)
pembrolizumab
Other Intervention Name(s)
KEYTRUDA
Intervention Description
pembrolizumab
Intervention Type
Drug
Intervention Name(s)
ipilimumab
Other Intervention Name(s)
YERVOY
Intervention Description
ipilimumab
Intervention Type
Drug
Intervention Name(s)
nivolumab
Other Intervention Name(s)
OPDIVO
Intervention Description
nivolumab
Primary Outcome Measure Information:
Title
Objective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1
Time Frame
Time from the date of randomization to the earliest date disease progression, or start of subsequent anticancer therapy, or death due to any cause (assessed up to approximately 48 months).
Secondary Outcome Measure Information:
Title
Progression Free Survival in each treatment arm
Time Frame
Time from the date of randomization to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first (assessed up to approximately 48 months)
Title
Overall Survival in each treatment arm
Time Frame
Time from date of randomization to the date of death due to any cause or the last known alive date (assessed up to approximately 48 months)
Title
Duration of Response (CR or PR) in each treatment arm
Time Frame
Time from the date of the first documented response (CR or PR) to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause (assessed up to approximately 48 months)
Title
Disease Control Rate (proportion of participants with a confirmed best overall response of CR, PR or SD) in each treatment arm
Time Frame
Time from the date of randomization to the earliest date of disease progression, or start of subsequent anticancer therapy (assessed up to approximately 48 months)
Title
Time to Response (CR or PR)
Time Frame
Time from the date of randomization to the date of first documented response (CR or PR), as determined by investigator assessment per RECIST v1.1 (assessed up to approximately 48 months)
Title
Progression Free Survival 2 in each treatment arm
Time Frame
Time from date of randomization to date of discontinuation of next-line treatment after 1st disease progression, 2nd disease progression after initiation of next line treatment, or death due to any cause (assessed up to approximately 48 months)
Title
Incidence and severity of Adverse Events (AEs) and changes in clinical laboratory parameters, vital signs, and cardiac assessments.
Description
Number of participants with treatment emergent Adverse Events as as assessed per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 4.03).
Time Frame
Time from first dose of study intervention through 28 days after the last dose of study intervention
Title
Patient Reported Outcomes using EORTC QLQ-C30 questionnaires in each treatment arm
Description
EORTC (European Organization for Research and Treatment of Cancer) QLQ-30 includes 5 functional scales (physical, role, emotional, cognitive and social functioning), 3 symptom scales (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial impact) and a global health status/Quality of Life scale
Time Frame
Change from Baseline until Progressive Disease, death, withdrawal of consent, lost to follow-up, or end of study, whichever occurs first (assessed up to approximately 48 months)
Title
Patient Reported Outcomes using EuroQOL EQ-5D-5L questionnaires in each treatment arm
Description
The EQ-5D-5L is a standardized measure of health utility that provides a single index value of health status and contains 1 item for each of 5 dimensions of HRQoL (ie, mobility, self-care, usual activities, pain or discomfort, and anxiety or depression).
Time Frame
Change from Baseline until Progressive Disease, death, withdrawal of consent, lost to follow-up, or end of study, whichever occurs first (assessed up to approximately 48 months)
Title
BRAF V600E/K Variant Allele Frequency and/or overall mean Variant Allele Frequency from circulating tumour DNA analysis in each treatment arm
Time Frame
Change from baseline, and Day 1 of Cycles 2, 3, 5, 7 (a cycle is every 3 or 4 weeks), and End of Treatment (assessed up to approximately 48 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female participants ≥18 years of age at the time of informed consent. Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic (Stage IV) cutaneous melanoma, according to the AJCC 8th edition. Documented evidence of a BRAF V600E or V600K mutation. Submission of adequate tumor tissue for central laboratory testing of BRAF V600E-mutation and biomarkers is required for all participants during the screening period and prior to randomization. Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) Must have anti-PD-1 resistant disease (primary or secondary) with confirmed disease progression per RECIST v1.1 either during or after receipt of an approved anti-PD-1 monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according to the SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020). Have at least one measurable lesion per RECIST v1.1. ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50% by cardiac imaging. Exclusion Criteria: Mucosal or ocular melanoma. Diagnosis of immunodeficiency or an active autoimmune disease that required systemic treatment with chronic systemic steroid therapy or any other form of immunosuppressive therapy within the past 2 years. Clinically significant cardiovascular diseases. History of thromboembolic or cerebrovascular events ≤12 weeks prior to randomization. History or current evidence of RVO or current risk factors for RVO. Concurrent neuromuscular disorder that is associated with the potential of elevated CK. Active bacterial, fungal, or viral infection requiring systemic therapeutic treatment within 2 weeks prior to randomization. Current non-infectious pneumonitis/interstitial lung disease or history of noninfectious pneumonitis/interstitial lung disease requiring steroids. Prior or current symptomatic brain metastasis, leptomeningeal disease or other active CNS metastases. Participants who permanently discontinued prior anti-PD-1 therapy due to toxicity or will be unable to tolerate combination therapy based on investigator judgement are excluded. Prior treatment with ipilimumab; prior combined immunotherapy blockade with anti-PD-1/L-1; prior treatment with a BRAFi and/or MEKi; or previous administration of an investigational anti-cancer agent for the adjuvant or first-line treatment of melanoma prior to randomization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pfizer CT.gov Call Center
Phone
1-800-718-1021
Email
ClinicalTrials.gov_Inquiries@pfizer.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Universitaetsklinikum Heidelberg
City
Heidelberg
State/Province
Baden-württemberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Universitaetsklinikum Tuebingen
City
Tübingen
State/Province
Baden-württemberg
ZIP/Postal Code
72076
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Medizinische Hochschule Hannover
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Name
Universitaetsklinikum Essen
City
Essen
State/Province
Nordrhein-westfalen
ZIP/Postal Code
45147
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Fachklinik Hornheide
City
Münster
State/Province
Nordrhein-westfalen
ZIP/Postal Code
48157
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Universitätsklinikum Leipzig
City
Leipzig
State/Province
Sachsen
ZIP/Postal Code
04103
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Helios Klinikum Erfurt
City
Erfurt
State/Province
Thüringen
ZIP/Postal Code
99089
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
A.O.U. Policlinico Paolo Giaccone
City
Palermo
State/Province
Sicilia
ZIP/Postal Code
90127
Country
Italy
Individual Site Status
Recruiting
Facility Name
Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
City
Candiolo
State/Province
Torino
ZIP/Postal Code
10060
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Azienda Ospedaliero Universitaria Senese
City
Siena
State/Province
Toscana
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Name
AO Santa Maria della Misericordia
City
Perugia
State/Province
Umbria
ZIP/Postal Code
06132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Ospedale San Martino
City
Genova
ZIP/Postal Code
16132
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Istituto Europeo di Oncologia IRCCS
City
Milano
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Istituto Nazionale Tumori IRCCS Fondazione Pascale
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Recruiting
Facility Name
Pratia MCM Krakow
City
Krakow
ZIP/Postal Code
30-727
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko - Mazurskim Centrum Onkologii
City
Olsztyn
ZIP/Postal Code
10-228
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Not yet recruiting
Facility Name
Fakultna Nemocnica s Poliklinikou F. D. Roosevelta Banska Bystrica
City
Banska Bystrica
ZIP/Postal Code
975 17
Country
Slovakia
Individual Site Status
Not yet recruiting
Facility Name
Narodny onkologicky ustav
City
Bratislava
ZIP/Postal Code
833 10
Country
Slovakia
Individual Site Status
Recruiting
Facility Name
Nemocnica na okraji mesta, n.o.
City
Partizanske
ZIP/Postal Code
95801
Country
Slovakia
Individual Site Status
Not yet recruiting
Facility Name
POKO Poprad, s.r.o., Ambulancia klinickej onkologie
City
Poprad
ZIP/Postal Code
058 01
Country
Slovakia
Individual Site Status
Not yet recruiting
Facility Name
Hospital Germans Trias i Pujol
City
Badalona
State/Province
Barcelona [barcelona]
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
State/Province
Barcelona [barcelona]
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Institut Català d'Oncologia - L'Hospitalet
City
L'Hospitalet de Llobregat
State/Province
Catalunya [cataluña]
ZIP/Postal Code
08908
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital General Universitario de Valencia
City
Valencia
State/Province
Valenciana, Comunitat
ZIP/Postal Code
46014
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clínic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital General Universitario Gregorio Marañon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Not yet recruiting
Facility Name
Hospital Universitario Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
IPD Sharing URL
https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=C4221023
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma

We'll reach out to this number within 24 hrs